Laponis Adam 4

What Happened
Adam Laponis, Chief Financial Officer of Twist Bioscience (TWST), sold 4,000 shares on April 17, 2026 at $60.00 per share, generating proceeds of $240,000. This was a sale (not a purchase or option exercise) and was executed pursuant to a previously adopted trading plan.

Key Details

• Transaction date: 2026-04-17; Filing date (Form 4): 2026-04-21 (filed within the SEC’s 2 business-day window).
• Transaction type/code: Sale (S) — open market or private sale reported.
• Shares sold: 4,000 at $60.00 each; total reported proceeds $240,000.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025 (pre-established plan).

Context
Sales by executives are common and often routine; a 10b5-1 plan indicates this sale was pre-arranged and should not be taken alone as a signal of changed company outlook. Purchases generally carry more weight for interpreting insider sentiment.